Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 45,00 € (+28,87 %). La médiane est de 44,55 € (+27,58 %).
| Acheter |
14 |
| Conserver |
2 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Roivant Sciences: investment three years ago would have returned 331.83%
An investment of $10,000 in Roivant Sciences three years ago would, according to calculations, have grown to $43,183.43, based on a current price of $36.49 per share and roughly 1,183.43 shares held. That corresponds to an increase of 331.83 percent. Market capitalization was most recently $26.36 billion; stock splits and dividends were not taken into account in the calculation. » Plus sur finanzen.net
Roivant presents pipeline and strong balance sheet at Citi summit
At the Citi “Biopharma Back to School Summit,” Roivant outlined its three strategic pillars: brepocitinib (LISRAYA) with FDA approval for dermatomyositis, the promising inhaled mosliciguat for PH‑ILD, and the FcRn antagonist IMVT‑1402 with strong early RA data. The company highlighted a robust liquidity position of $3.9 billion (plus an expected Moderna contingent payment of >$700 million) and a market capitalization near $30 billion, which it says provides room for development and business activities. Roivant announced several near‑term catalysts (Phase III/II data in 2026–2027), but is pursuing a moderate launch and pricing strategy and noted an ongoing legal dispute related to an LNP study. » Plus sur de.investing.com
Roivant: strong mosliciguat data drive pipeline development forward
Roivant presented convincing phase II data on mosliciguat at a conference, showing the strongest ever measured reduction in pulmonary vascular resistance and expanding indication planning beyond PH‑ILD. Brepocitinib was introduced early for dermatomyositis and received positive initial feedback, while IMVT‑1402 (FcRn program) is considered the third major long‑term project, with an important Graves' disease phase III program planned for 2027. Management emphasizes that operational capacity (simultaneous phase III studies) is the main constraint on growth, not capital; patent protection for mosliciguat extends into the mid‑2040s. » Plus sur de.investing.com
Roivant presents strong pipeline data and begins market launch of LISRAYA
At the Wells Fargo healthcare conference Roivant reported positive clinical results: mosliciguat showed a placebo‑adjusted reduction in pulmonary vascular resistance of 56% in PH‑ILD and is moving into a phase III study, while LISRAYA (brepocitinib) was just approved for the treatment of dermatomyositis and initial prescriptions have been written. IMVT‑1402, an FcRn inhibitor, produced strong IgG suppression and promising signals across multiple autoimmune indications, including difficult‑to‑treat rheumatoid arthritis, Graves’ disease and myasthenia gravis. Management emphasized focused commercialization in orphan indications, possible near‑term catalysts, and noted regulatory and launch risks; the company was valued at just under $30bn at the time of the conference. » Plus sur de.investing.com
Roivant presents phase-2 data on pulmonary hypertension drug mosliciguat
Roivant and Pulmovant announce they will present the phase-2 PHocus study of mosliciguat for pulmonary hypertension in interstitial lung disease on September 8, 2026, at the ERS Congress. Marc Humbert will present the results; Roivant will hold a conference call with webcast the same day at 8:00 a.m. ET, accessible on the investor site. Mosliciguat is an inhaled sGC activator; Roivant’s pipeline also includes LISRAYA (brepocitinib), approved by the FDA for dermatomyositis, and the anti‑FcRn antibody IMVT‑1402. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 31,01 M | 2 216,18 % |
| Bénéfice brut | 28,05 M | 2 154,76 % |
| Bénéfice net | -169,17 M | 74,88 % |
| EBITDA | -146,32 M | 8,60 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 25,24 Md € |
Nombre d'actions | 724,56 M |
Plus haut/bas sur 52 semaines | 38,64 € - 18,15 € |
| Dividendes | Non |
Bêta | 1,20 |
Ratio P/E | -79,83 |
Ratio PEG | 0,71 |
Ratio P/B | 6,89 |
Ratio P/S | 675,79 |
Profil de l'entreprise
Roivant Sciences Ltd., une société de biopharmaceutique et de technologies de santé qui recherche et développe des médicaments. La société développe des candidats-médicaments pour le traitement de diverses pathologies, notamment les tumeurs solides, la drépanocytose, l'hypophosphatasie, les hémopathies malignes, le psoriasis, la dermatite atopique, le vitiligo, l'hyperhidrose, l'acné, la myasthénie grave, l'anémie hémolytique auto-immune à anticorps chauds, l'ophtalmopathie thyroïdienne, la sarcoïdose et la bactériémie à Staphylococcus aureus. La société a été fondée en 2014 et est basée à Londres, au Royaume-Uni.
| Nom | Roivant Sciences |
| PDG | Matthew Gline |
| Siège social | London,
gl États-Unis |
| Site web | |
| Secteur | Santé |
| Industrie | Produits pharmaceutiques |
| Introduction en bourse | 08/12/2020 |
| Employés | 721 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ROIV |
Frankfurt | 87S.F |
Düsseldorf | 87S.DU |
München | 87S.MU |